Xilio Therapeutics, Inc.

XLO

Held by 0 specialist biotech funds

Fund Holdings

XLO is not currently held by any of our tracked specialist biotech funds.

Fund positions update quarterly with new 13F filings. Explore fund convergence to see which tickers multiple funds hold.

Short Interest

Short Shares

159K

Change

+3.5%

Days to Cover

5.2

% of Float

0.3%

Settlement

Mar 13, 2026

Short interest over 2 periods

Catalysts

No catalysts tracked.

Activist Filings

SC 13G/ARA Capital Management0.0%Nov 14, 2022

SC 13G/ARA Capital Management7.3%Feb 14, 2022

SC 13GRA Capital Management5.7%Nov 5, 2021

Recent Insider Activity

Shannon James SamuelDirector

PurchaseMar 30, 2026

Unlock dollar amounts, share counts, and AI context with a free trial.

Position Details

No position data available.

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 7-Day Free Trial — $29/mo

Insider Signals

Shannon James SamuelDirectorBuyMar 30, 2026SEC Filing →

Shares: 5,000Value: $43,950Price: $8.79

XLO - Director Purchase Signal

Director Samuel's $44K purchase of 5,000 shares at $8.79 represents meaningful personal conviction at current valuation levels. The timing and size suggest confidence ahead of upcoming catalysts; monitor for clinical readouts or partnership announcements that may have triggered the buy.

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief: